In a bleomycin-induced model of IPF, the NTB-loaded β-CD MPs demonstrated therapeutic efficacy by reducing levels of the pro-inflammatory cytokine IFNɣ and chemokine LIX, as well as lowering levels of the chemokines IP-10 and MCP-1. The gene discussed is CCL2; the disease is idiopathic pulmonary fibrosis.